Literature DB >> 10677500

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

J Li1, I Sarosi, X Q Yan, S Morony, C Capparelli, H L Tan, S McCabe, R Elliott, S Scully, G Van, S Kaufman, S C Juan, Y Sun, J Tarpley, L Martin, K Christensen, J McCabe, P Kostenuik, H Hsu, F Fletcher, C R Dunstan, D L Lacey, W J Boyle.   

Abstract

We have generated RANK (receptor activator of NF-kappaB) nullizygous mice to determine the molecular genetic interactions between osteoprotegerin, osteoprotegerin ligand, and RANK during bone resorption and remodeling processes. RANK(-/-) mice lack osteoclasts and have a profound defect in bone resorption and remodeling and in the development of the cartilaginous growth plates of endochondral bone. The osteopetrosis observed in these mice can be reversed by transplantation of bone marrow from rag1(-/-) (recombinase activating gene 1) mice, indicating that RANK(-/-) mice have an intrinsic defect in osteoclast function. Calciotropic hormones and proresorptive cytokines that are known to induce bone resorption in mice and human were administered to RANK(-/-) mice without inducing hypercalcemia, although tumor necrosis factor alpha treatment leads to the rare appearance of osteoclast-like cells near the site of injection. Osteoclastogenesis can be initiated in RANK(-/-) mice by transfer of the RANK cDNA back into hematopoietic precursors, suggesting a means to critically evaluate RANK structural features required for bone resorption. Together these data indicate that RANK is the intrinsic cell surface determinant that mediates osteoprotegerin ligand effects on bone resorption and remodeling as well as the physiological and pathological effects of calciotropic hormones and proresorptive cytokines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677500      PMCID: PMC26475          DOI: 10.1073/pnas.97.4.1566

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.

Authors:  B R Wong; J Rho; J Arron; E Robinson; J Orlinick; M Chao; S Kalachikov; E Cayani; F S Bartlett; W N Frankel; S Y Lee; Y Choi
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses.

Authors:  Y Xu; G Cheng; D Baltimore
Journal:  Immunity       Date:  1996-11       Impact factor: 31.745

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Requirement for NF-kappaB in osteoclast and B-cell development.

Authors:  G Franzoso; L Carlson; L Xing; L Poljak; E W Shores; K D Brown; A Leonardi; T Tran; B F Boyce; U Siebenlist
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

5.  Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.

Authors:  V Iotsova; J Caamaño; J Loy; Y Yang; A Lewin; R Bravo
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice.

Authors:  W C Yeh; A Shahinian; D Speiser; J Kraunus; F Billia; A Wakeham; J L de la Pompa; D Ferrick; B Hum; N Iscove; P Ohashi; M Rothe; D V Goeddel; T W Mak
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

7.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

9.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.

Authors:  A E Grigoriadis; Z Q Wang; M G Cecchini; W Hofstetter; R Felix; H A Fleisch; E F Wagner
Journal:  Science       Date:  1994-10-21       Impact factor: 47.728

10.  Bone and haematopoietic defects in mice lacking c-fos.

Authors:  Z Q Wang; C Ovitt; A E Grigoriadis; U Möhle-Steinlein; U Rüther; E F Wagner
Journal:  Nature       Date:  1992 Dec 24-31       Impact factor: 49.962

View more
  278 in total

Review 1.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 2.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

3.  Interactions between immune and bone cells: new insights with many remaining questions.

Authors:  J Lorenzo
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 4.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

5.  Osteoporosis and gastrointestinal disease.

Authors:  Seymour Katz; Stuart Weinerman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

6.  RANKing c-Jun in osteoclast development.

Authors:  Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 7.  Bone, inflammation, and inflammatory bowel disease.

Authors:  Manasi Agrawal; Shitij Arora; Jianjun Li; Rabin Rahmani; Li Sun; Adam F Steinlauf; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

8.  Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice.

Authors:  Firas M Kara; Stephen B Doty; Adele Boskey; Steven Goldring; Mone Zaidi; Bertil B Fredholm; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2010-02

9.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

Review 10.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.